Pain management in intellectually disabled children: Assessment, treatment, and translational research

Developmental Disabilities Research Reviews

Volumn 16, Issue 3, 2010, Pages 248-257

  Valkenburg, Abraham J ^a   van Dijk, Monique ^a   de Klein, Annelies ^b   van den Anker, Johannes N ^c   Tibboel, Dick ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Analgesia; Down syndrome; Intellectual disability; Pain assessment; Translational research

Indexed keywords

ADAM PROTEIN; ANALGESIC AGENT; ANTICONVULSIVE AGENT; CALGRANULIN B; GLUTAMATE RECEPTOR; METHOTREXATE; MORPHINE; MUSCLE RELAXANT AGENT; OPIATE; PARACETAMOL; POTASSIUM CHANNEL KCNE1; POTASSIUM CHANNEL KCNQ2; PSYCHOTROPIC AGENT; SEDATIVE AGENT; THEOPHYLLINE; THYROID HORMONE; TRANSCRIPTION FACTOR RUNX1; VINCRISTINE; NARCOTIC ANALGESIC AGENT;

BEHAVIOR CHANGE; CHROMOSOME DISORDER; CLINICAL OBSERVATION; DOWN SYNDROME; EPILEPSY; FACIAL EXPRESSION; GASTROESOPHAGEAL REFLUX; GENOTYPE PHENOTYPE CORRELATION; HANDICAPPED CHILD; HUMAN; INTELLECTUAL IMPAIRMENT; OBSERVATIONAL METHOD; PAIN ASSESSMENT; POSTOPERATIVE CARE; POSTOPERATIVE PAIN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RESPIRATORY TRACT DISEASE; REVIEW; SELF EVALUATION; SELF REPORT; TRANSLATIONAL RESEARCH; VISUAL ANALOG SCALE; VOICE CHANGE; ADOLESCENT; ADULT; ANIMAL; BLOOD; CHILD; DISEASE MODEL; DOSE RESPONSE; DRUG COMBINATION; GENETIC ASSOCIATION; GENETICS; GENOTYPE; INFANT; MENTAL DEFICIENCY; METHODOLOGY; MOUSE; PHARMACOGENETICS; PHENOTYPE; PRESCHOOL CHILD; PSYCHOLOGICAL ASPECT;

ADOLESCENT; ADULT; ANALGESICS, OPIOID; ANIMALS; CHILD; CHILD, PRESCHOOL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN SYNDROME; DRUG THERAPY, COMBINATION; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; INFANT; MENTAL RETARDATION; MICE; MORPHINE; PAIN MEASUREMENT; PAIN, POSTOPERATIVE; PHARMACOGENETICS; PHENOTYPE; TRANSLATIONAL RESEARCH; YOUNG ADULT;

EID: 79952796344     PISSN: 19405510     EISSN: 10982779     Source Type: Journal    
DOI: 10.1002/ddrr.117     Document Type: Review

References (88)

1. Anand KJ, Craig KD. 1996. New perspectives on the definition of pain. Pain 67:3-6; discussion 209-211.
2. Arendt-Nielsen L, Yarnitsky D. 2009. Experimental and clinical applications of quantitative sensory testing applied to skin, muscles and viscera. J Pain 10:556-572.
3. Arnaud C, White-Koning M, Michelsen SI, et al. 2008. Parent-reported quality of life of children with cerebral palsy in Europe. Pediatrics 121:54-64.
4. Beavis J, Kerr M, Marson AG. 2007. Pharmacological interventions for epilepsy in people with intellectual disabilities. Cochrane Database Syst Rev CD005399.
5. Berde C, McGrath P. 2009. Pain measurement and Beecher's challenge: 50 years later. Anesthesiology 111:473-474.
6. Biersdorff KK. 1991. Pain insensitivity and indifference: alternative explanations for some medical catastrophes. Ment Retard 29:359-362.
7. Blankenburg M, Boekens H, Hechler T, et al. 2010. Reference values for quantitative sensory testing in children and adolescents: developmental and gender differences of somatosensory perception. Pain 149:76-88.
8. Bohmer CJ, Klinkenberg-Knol EC, Niezen-de Boer MC, et al. 2000. Gastroesophageal reflux disease in intellectually disabled individuals: how often, how serious, how manageable? Am J Gastroenterol 95:1868-1872.
9. Bouwmeester NJ, Anderson BJ, Tibboel D, et al. 2004. Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. Br J Anaesth 92:208-217.
10. Breau L. 2010. The science of pain measurement and the frustration of clinical pain assessment: does an individualized numerical rating scale bridge the gap for children with intellectual disabilities? Pain 150:213-214.
11. Breau LM, Burkitt C. 2009. Assessing pain in children with intellectual disabilities. Pain Res Manag 14:116-120.
12. Breau LM, McGrath PJ, Zabalia M. 2006. Assessing pediatric pain and developmental disabilities. In: Oberlander TF, Symons FJ, editors. Pain in children and adults with developmental disabilities. Baltimore, MD: Paul H. Brookes Publishing Co. p 149-172.
13. Buitenkamp TD, Mathôt RAA, de Haas V, et al. 2010. Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia. Haematologica 95:1106-1113.
14. Chapman RS, Hesketh LJ. 2000. Behavioral phe-notype of individuals with Down syndrome. Ment Retard Dev Disabil Res Rev 6:84-95.
15. Cleves MA, Hobbs CA, Cleves PA, et al. 2007. Congenital defects among liveborn infants with Down syndrome. Birth Defects Res Part A Clin Mol Teratol 79:657-663.
16. Couston TA. 1954. Indifference to pain in low-grade mental defectives. Br Med J 1: 1128-1129.
17. Czarnecki ML, Ferrise AS, Jastrowski Mano KE, et al. 2008. Parent/nurse-controlled analgesia for children with developmental delay. Clin J Pain 24:817-824.
18. de Bildt A, Kraijer D, Sytema S, Minderaa R. 2005. The psychometric properties of the Vineland Adaptive Behavior Scales in children and adolescents with mental retardation. J Autism Dev Disord. 35:53-62.
19. de Bildt A, Mulder EJ, Scheers T, et al. 2006. Pervasive developmental disorder, behavior problems, and psychotropic drug use in children and adolescents with mental retardation. Pediatrics 118:e1860-1866.
20. De Cock RF, Piana C, Krekels EH, et al. 2010. The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol DOI: 10.1007/s00228-009-0782-9.
21. Defrin R, Pick CG, Peretz C, et al. 2004. A quantitative somatosensory testing of pain threshold in individuals with mental retardation. Pain 108:58-66.
22. Dykens EM, Hodapp RM, Evans DW. 2006. Profiles and development of adaptive behavior in children with Down syndrome. Downs Syndr Res Pract 9:45-50.
23. Eriksson AS, Hoppu K, Nergardh A, et al. 1996. Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy. Epilepsia 37:769-773.
24. Fanurik D, Koh JL, Schmitz ML, et al. 1999a. Children with cognitive impairment: parent report of pain and coping. J Dev Behav Pediatr 20:228-234.
25. Fanurik D, Koh JL, Schmitz ML, et al. 1999b. Pain assessment and treatment in children with cognitive impairment: a survey of nurses' and physicians' beliefs. Clin J Pain 15:304-312.
26. Freeman SB, Allen EG, Oxford-Wright CL, et al. 2007. The national Down syndrome project: design and implementation. Public Health Rep 122:62-72.
27. Freeman SB, Bean LH, Allen EG, et al. 2008. Ethnicity, sex, and the incidence of congenital heart defects: a report from the national Down syndrome project. Genet Med 10:173-180.
28. Freeman SB, Torfs CP, Romitti PA, et al. 2009. Congenital gastrointestinal defects in Down syndrome: a report from the Atlanta and national Down syndrome projects. Clin Genet 75:180-184.
29. Friesen RH, Williams GD. 2008. Anesthetic management of children with pulmonary arterial hypertension. Paediatr Anaesth 18: 208-216.
30. Gakhal B, Scott CS, MacNab AJ. 1998. Comparison of morphine requirements for sedation in Down's syndrome and non-Down's patients following paediatric cardiac surgery. Paediatr Anaesth 8:229-233.
31. Ghai B, Makkar JK, Wig J. 2008. Postoperative pain assessment in preverbal children and children with cognitive impairment. Paediatr Anaesth 18:462-477.
32. Glaze DG, Percy AK, Skinner S, et al. 2010. Epilepsy and the natural history of Rett syndrome. Neurology 74:909-912.
33. Goldberg-Stern H, Strawsburg RH, Patterson B, et al. 2001. Seizure frequency and characteristics in children with Down syndrome. Brain Dev 23:375-378.
34. Gordon DB, Rees SM, McCausland MR, et al. 2008. Improving reassessment and documentation of pain management. Joint Commission J Qual Patient Saf Joint Commission Resour 34:509-517.
35. Griener JC, Msall ME, Cooke RE, et al. 1990. Noninvasive determination of acetaminophen disposition in Down's syndrome. Clin Pharmacol Ther 48:520-528.
36. Halpern LM, Jolley SG, Johnson DG. 1991. Gastroesophageal reflux: a significant association with central nervous system disease in children. J Pediatr Surg 26:171-173.
37. Hattori M, Fujiyama A, Taylor TD, et al. 2000. The DNA sequence of human chromosome 21. Nature 405:311-319.
38. Hennequin M, Morin C, Feine J. 2000. Pain expression and stimulus localisation in individuals with Down's syndrome. Lancet 356:1882-1887.
39. Hunt A, Goldman A, Seers K, et al. 2004. Clinical validation of the paediatric pain profile. Dev Med Child Neurol 46:9-18.
40. Kearns GL, Abdel-Rahman SM, Alander SW, et al. 2003. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med 349:1157-1167.
41. Kerins G, Petrovic K, Bruder MB, et al. 2008. Medical conditions and medication use in adults with Down syndrome: a descriptive analysis. Downs Syndr Res Pract 12:141-147.
42. Kingston K, Bailey C. 2009. Assessing the pain of people with a learning disability. Br J Nurs 18:420-423.
43. Knibbe CAJ, Krekels EHJ, van den Anker JN, et al. 2009. Morphine glucuronidation in preterm neonates, infants and children younger than 3 years. Clin Pharmacokinet 48:371-385.
44. Kofke WA. 2010. Anesthetic management of the patient with epilepsy or prior seizures. Curr Opin Anaesthesiol 23:391-399.
45. Koh JL, Fanurik D, Harrison RD, et al. 2004. Analgesia following surgery in children with and without cognitive impairment. Pain 111:239-244.
46. Kulak W, Sobaniec W, Smigielska-Kuzia J, et al. 2005. A comparison of spastic diplegic and tetraplegic cerebral palsy. Pediatr Neurol 32:311-317.
47. Lacroix-Fralish ML, Ledoux JB, Mogil JS. 2007. The pain genes database: an interactive web browser of pain-related transgenic knockout studies. Pain 131:3.e1-4.
48. Long LS, Ved S, Koh JL. 2009. Intraoperative opioid dosing in children with and without cerebral palsy. Paediatr Anaesth. 19:513-20.
49. Lönnerholm G, Frost B-M, Söderhäll S, et al. 2009. Vincristine pharmacokinetics in children with Down syndrome. Pediatr Blood Cancer 52:123-125.
50. Lott IT, Dierssen M. 2010. Cognitive deficits and associated neurological complications in individuals with Down's syndrome. Lancet Neurol 9:623-633.
51. Maier C, Baron R, Tölle TR, et al. 2010. Quantitative sensory testing in the German research network on neuropathic pain (DFNS): somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes. Pain 1-12.
52. Malviya S, Voepel-Lewis T, Merkel S, et al. 2005. Difficult pain assessment and lack of clinician knowledge are ongoing barriers to effective pain management in children with cognitive impairment. Acute Pain 7:27-32.
53. Malviya S, Voepel-Lewis T, Tait AR, et al. 2001. Pain management in children with and without cognitive impairment following spine fusion surgery. Paediatr Anaesth 11:453-458.
54. Martínez-Cué C, Baamonde C, Lumbreras MA, et al. 1999. A murine model for Down syndrome shows reduced responsiveness to pain. Neuroreport 10:1119-1122.
55. Mik G, Gholve PA, Scher DM, et al. 2008. Down syndrome: orthopedic issues. Curr Opin Pediatr 20:30-36.
56. Mitchell V, Howard R, Facer E. 1995. Down's syndrome and anaesthesia. Paediatr Anaesth 5:379-384.
57. Nielsen CS, Staud R, Price DD. 2009. Individual differences in pain sensitivity: measurement, causation, and consequences. J Pain 10:231-237.
58. Oberlander T, Saul JP 2002. Methodological considerations for the use of heart rate variability as a measure of pain reactivity in vulnerable infants. Clin Perinatol 29:427-443.
59. Prins SA, van Dijk M, Van Leeuwen P, et al. 2008. Pharmacokinetics and analgesic effects of intravenous propacetamol vs. rectal paracetamol in children after major craniofacial surgery. Paediatr Anaesth 18:582-592.
60. Reed MD, Rodarte A, Blumer JL, et al. 2001. The single-dose pharmacokinetics of midazolam and its primary metabolite in pediatric patients after oral and intravenous administration. J Clin Pharmacol 41:1359-1369.
61. Roberts JE, Price J, Malkin C. 2007. Language and communication development in Down syndrome. Ment Retard Dev Disabil Res Rev 13:26-35.
62. Rolke R, Baron R, Maier C, et al. 2006. Quantitative sensory testing in the German research network on neuropathic pain (DFNS): standardized protocol and reference values. Pain 123:231-243.
63. Salehi A, Faizi M, Belichenko PV, et al. 2007. Using mouse models to explore genotype-phenotype relationship in Down syndrome. Ment Retard Dev Disabil Res Rev 13:207-214.
64. Slater R, Fitzgerald M, Meek J. 2007. Can cortical responses following noxious stimulation inform us about pain processing in neonates? Semin Perinatol 31:298-302.
65. Solodiuk JC, Scott-Sutherland J, Meyers M, et al. 2010. Validation of the individualized numeric rating scale (INRS): a pain assessment tool for nonverbal children with intellectual disability. Pain 150:231-236.
66. Stengel E, Oldham AJ, Ehrenberg AS. 1958. Reactions of low-grade mental defectives to pain. J Ment Sci 104:434-438.
67. Stevens BJ, Pillai Riddell RR, Oberlander TF, et al. 2007. Assessment of pain in neonates and infants. In: Anand KJS, Stevens BJ, McGrath PJ, editors. Pain in neonates and infants. p 67-90.
68. Storm H. 2008. Changes in skin conductance as a tool to monitor nociceptive stimulation and pain. Curr Opin Anaesthesiol 21:796-804.
69. Stowe CD, Phelps SJ. 1999. Altered clearance of theophylline in children with Down syndrome: a case series. J Clin Pharmacol 39:359-365.
70. Symons FJ, Harper V, Shinde SK, et al. 2010. Evaluating a sham-controlled sensory-testing protocol for nonverbal adults with neurode-velopmental disorders: self-injury and gender effects. J Pain 11:773-781.
71. 't Jong GW, Vulto AG, de Hoog M, et al. 2000. Unapproved and off-label use of drugs in a children's hospital. N Engl J Med 343:1125.
72. Taddio A, Oberlander TF. 2006. Pharmalogical management of pain in children and youth with significant neurological impairments. In: Oberlander TF, Symons FJ, editors. Pain in children and adults with developmental disabilities. Baltimore, MD: Paul H. Brookes Publishing Co. p 193-211.
73. Tempelhoff R, Modica PA, Spitznagel EL. 1990. Anticonvulsant therapy increases fentanyl requirements during anaesthesia for craniotomy. Can J Anaesth 37:327-332.
74. Terstegen C, Koot HM, de Boer JB, et al. 2003. Measuring pain in children with cognitive impairment: pain response to surgical procedures. Pain 103:187-198.
75. Tod M, Jullien V, Pons G. 2008. Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokinet 47:231-243.
76. Valkenburg AJ, de Leeuw TG, Tibboel D, et al. 2009. Lower bispectral index values in children who are intellectually disabled. Anesth Analg 109:1428-1433.
77. van Dijk M, Valkenburg A, Boerlage AA, et al. 2009. Children with intellectual disabilities and pain perception: a review and suggestions for future assessment protocols. Eur Arch Paediatr Dent 10:57-60.
78. Vetter TR, Carvallo D, Johnson JL, et al. 2007. A comparison of single-dose caudal clonidine, morphine, or hydromorphone combined with ropivacaine in pediatric patients undergoing ureteral reimplantation. Anesth Analg 104:1356-1363.
79. Vis JC, Duffels MGJ, Winter MM, et al. 2009. Down syndrome: a cardiovascular perspective. J Intellect Disabil Res 53:419-425.
80. Voepel-Lewis T, Malviya S, Tait AR, et al. 2008. A comparison of the clinical utility of pain assessment tools for children with cognitive impairment. Anesth Analg 106: 72-78.
81. von Baeyer CL. 2009. Numerical rating scale for self-report of pain intensity in children and adolescents: recent progress and further questions. Eur J Pain 13:1005-1007.
82. Weijerman ME, de Winter JP. 2010. Clinical practice: the care of children with Down syndrome. Eur J Pediatr. DOI: 10.1007/s00431-010-1253-0.
83. Weijerman ME, van Furth AM, Vonk Noorde-graaf A, et al. 2008. Prevalence, neonatal characteristics, and first-year mortality of Down syndrome: a national study. J Pediatr 152:15-19.
84. Werner MU, Mjöbo HN, Nielsen PR, et al. 2010. Prediction of postoperative pain: a systematic review of predictive experimental pain studies. Anesthesiology 112:1494-1502.
85. Westerinen H, Kaski M, Virta L, et al. 2007. Prevalence of intellectual disability: a comprehensive study based on national registers. J Intellect Disabil Res 51(Part 9):715-725.
86. Wullink M, van Schrojenstein Lantman-de Valk HMJ, Dinant GJ, et al. 2007. Prevalence of people with intellectual disability in the Netherlands. J Intellect Disabil Res 51 (Part 7):511-519.
87. Yuen VM, Hui TW, Irwin MG, et al. 2008. A comparison of intranasal dexmedetomidine and oral midazolam for premedication in pediatric anesthesia: a double-blinded randomized controlled trial. Anesth Analg 106:1715-1721.
88. Zwaan CM, Reinhardt D, Hitzler J, et al. 2010. Acute leukemias in children with Down syndrome. Hematol Oncol Clin North Am 24:19-34.